Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals (APLS) Stock Price & Analysis


APLS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$37.66 - $94.45
Previous Close$92.13
Average Volume (3M)1.65M
Market Cap
Enterprise Value$10.07B
Total Cash (Recent Filing)$766.38M
Total Debt (Recent Filing)$111.87M
Price to Earnings (P/E)-14.7
Aug 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.28
Shares Outstanding116,457,008
10 Day Avg. Volume1,041,931
30 Day Avg. Volume1,650,634
Standard Deviation0.18
Financial Highlights & Ratios
Price to Book (P/B)26.42
Price to Sales (P/S)177.96
Price to Cash Flow (P/CF)-15.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue95.15
Enterprise Value/Gross Profit144.37
Enterprise Value/Ebitda-15.31
Price Target Upside15.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $37.66 and its highest was $94.45 in the past 12 months.
    What is Apellis Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
    Apellis Pharmaceuticals Inc’s upcoming earnings report date is Aug 07, 2023 which is in 59 days.
      How were Apellis Pharmaceuticals Inc’s earnings last quarter?
      Apellis Pharmaceuticals Inc released its earnings results on May 04, 2023. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.478 by -$0.082.
        Is Apellis Pharmaceuticals Inc overvalued?
        According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Apellis Pharmaceuticals Inc pay dividends?
          Apellis Pharmaceuticals Inc does not currently pay dividends.
          What is Apellis Pharmaceuticals Inc’s EPS estimate?
          Apellis Pharmaceuticals Inc’s EPS estimate is -$1.37.
            How many shares outstanding does Apellis Pharmaceuticals Inc have?
            Apellis Pharmaceuticals Inc has 116,457,010 shares outstanding.
              What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
              Apellis Pharmaceuticals Inc reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.478. Following the earnings report the stock price went up 10.442%.
                Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
                Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds Apellis Pharmaceuticals Inc’s shares valued at 37M.


                  Apellis Pharmaceuticals Stock Smart Score

                  The Apellis Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Apellis Pharmaceuticals Inc

                  Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.


                  Top 5 ETFs holding APLS

                  Market Value
                  Smart Score
                  Vanguard Health Care ETF
                  iShares Core S&P Total U.S. Stock Market ETF
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Schwab U.S. Broad Market ETF
                  Fidelity MSCI Health Care Index ETF
                  Up to five ETFs with an Outperform Smart Score that hold APLS. The ETFs are listed according to market value of APLS within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Rocket Pharmaceuticals
                  Crispr Therapeutics AG
                  Ultragenyx Pharmaceutical
                  Bluebird Bio

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis